Arixtra approved for superficial-vein thrombosis

Arixtra (fondaparinux) has been approved for the treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (DVT).

Treatment should be initiated as soon as possible following diagnosis and after exclusion of concomitant DVT or superficial-vein thrombosis within 3cm of the sapheno-femoral junction.

Therapy with Arixtra should be continued for ?30—45 days. Patients may self inject if willing ?and able to do so, following clear instruction by their physician.

View Arixtra drug record

Further information: GlaxoSmithKline